Medifast announced its fourth quarter and full year 2024 financial results, with Q4 revenue decreasing 37.7% to $119.0 million from $191.0 million in Q4 2023, primarily due to a decrease in active earning OPTAVIA coaches and lower coach productivity. Net income for Q4 2024 was $0.8 million, or $0.07 per diluted share.
Fourth quarter 2024 revenue decreased 37.7% to $119.0 million.
Net income for Q4 2024 was $0.8 million, with diluted EPS of $0.07.
Independent active earning OPTAVIA coaches decreased 34.1% to 27,100.
Cash, Cash Equivalents, and Investment Securities stood at $162.3 million with no debt.
The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share.
Analyze how earnings announcements historically affect stock price performance